<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03993249</url>
  </required_header>
  <id_info>
    <org_study_id>REQ-0000020479</org_study_id>
    <nct_id>NCT03993249</nct_id>
  </id_info>
  <brief_title>Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy</brief_title>
  <official_title>Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy: a Phase II, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic GenitoUrinary Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hellenic GenitoUrinary Cancer Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect synchronous use of nivolumab in&#xD;
      addition to chemoradiotherapy in patients withnon-metastatic MIBC who are not candidates for&#xD;
      radical cystectomy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The initial hypothesis is that addition of nivolumab will increase 2-year locoregional&#xD;
      control rate from 55% (control arm) to 75% (immunotherapy arm)&#xD;
&#xD;
      There is a 24 month accrual period during which 78 patients will be randomized in a control&#xD;
      group (standard chemo-radiotherapy) and the treatment group (chemo-radiotherapy + Nivolumab)&#xD;
&#xD;
      The primary objective would be to compare locoregional control rate at 2-years between&#xD;
      patients with MIBC receiving or not receiving nivolumab in addition to chemoradiotherapy.&#xD;
&#xD;
      The secondary objectives are&#xD;
&#xD;
        1. To study the safety of the addition of nivolumab to chemoradiotherapy in patients with&#xD;
           MIBC&#xD;
&#xD;
        2. To compare 2-year bladder cancer failure-free (BCFF) rates, defined as distant&#xD;
           metastasis free survival (MFS) AND/OR locoregional failure (defined as in primary&#xD;
           objective)&#xD;
&#xD;
        3. To compare median overall survival (OS) in patients with MIBC receiving or not receiving&#xD;
           nivolumab in addition to chemoradiotherapy&#xD;
&#xD;
        4. Assess the effect of combined treatment on the quality of life&#xD;
&#xD;
      Correlative studies of outcomes with PD-L1expression and with lymphocytic populations in the&#xD;
      environment of the tumor&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Locoregional control rate</measure>
    <time_frame>2 years</time_frame>
    <description>To compare locoregional control rate at 2-years between patients with MIBC receiving or not receiving nivolumab in addition to chemoradiotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of treatment-related adverse event (safety and tolerability)</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of adverse events as assessed by CTCAE. After radiotherapy completion, AEs will be assessed according to RTOG/EORTC Late Radiation Morbidity Scoring Schema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bladder cancer failure-free (BCFF) rates</measure>
    <time_frame>2 years</time_frame>
    <description>To compare 2-year bladder cancer failure-free (BCFF) rates, defined as distant metastasis free survival (MFS) AND/OR locoregional failure (defined as in primary objective)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>To compare median overall survival (OS) in patients with MIBC receiving or not receiving nivolumab in addition to chemoradiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the effect of the combined treatment on the quality of life</measure>
    <time_frame>2 years</time_frame>
    <description>Quality of life score assessed by Quality of Life of Cancer Patients Questionnaire (EORTC QLQ-C30). Discomfort measured in a scale from 1 (not at all) to 4 (very much) Overall health and quality of life score measured in a scale from 1 (very poor) to 7 (excellent)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>standard of care chemo-radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard of care chemo-radiotherapy + Nivolumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>standard of care chemoradiotherapy + Nivolumab</description>
    <arm_group_label>Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>chemoradiotherapy</intervention_name>
    <description>standard of care chemoradiotherapy</description>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <arm_group_label>Combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven, muscle-invasive carcinoma of the bladder, cT2-T4aN0M0&#xD;
&#xD;
          -  Urothelial, squamous or glandular histology according to WHO 2016 classification (Fig&#xD;
             1)&#xD;
&#xD;
          -  Undergone a vigorous TURB&#xD;
&#xD;
          -  Not candidates for radical cystectomy.&#xD;
&#xD;
          -  PS:0-1&#xD;
&#xD;
          -  age &gt;18 years old&#xD;
&#xD;
          -  Adequate bone marrow function&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Key Exclusion Criteria&#xD;
&#xD;
          -  Histology other than transitional-cell, squamous or adenocarcinoma&#xD;
&#xD;
          -  Prior malignancy active within the previous 3 years except for locally curable cancers&#xD;
             that have been apparently cured, such as basal or squamous cell skin cancer, prostate&#xD;
             cancer cervix or breast.&#xD;
&#xD;
          -  Previous systemic chemotherapy or prior biologic agents within 4 weeks, or&#xD;
             intravesical Bacillus Calmette-Guerin (BCG) within 6 weeks of the first dose of study&#xD;
             treatment.&#xD;
&#xD;
          -  Prior treatment with any PD-1 or PDL-1 inhibitor or anti CTLA4 agent&#xD;
&#xD;
          -  Previous pelvic radiation therapy.&#xD;
&#xD;
          -  Patients with inherited syndromes associated with hypersensitivity to ionizing&#xD;
             radiation&#xD;
&#xD;
          -  Any serious or uncontrolled medical disorder that, in the opinion of the investigator,&#xD;
             may increase the risk associated with study participation&#xD;
&#xD;
          -  Any history of inflammatory bowel disease and or history of abdominal fistula&#xD;
&#xD;
          -  Previous allergy to any of the study drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vasiliki Magoula, MSc</last_name>
    <phone>+302107777791</phone>
    <email>res2@eeoogek.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hellenic GenitoUrinary Cancer Group</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aristotelis Bamias, Professor</last_name>
      <phone>00302107777791</phone>
      <email>abamias@med.uoa.gr</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

